Riik: Austraalia
keel: inglise
Allikas: APVMA (Australian Pesticides and Veterinary Medicines Authority)
CLOSTRIDIUM CHAUVOEI - FORMOL CULTURE; CLOSTRIDIUM NOVYI TYPE B; CLOSTRIDIUM PERFRINGENS TYPE D TOXOID; CLOSTRIDIUM SEPTICUM - TOXOID; TETANUS = CLOSTRIDIUM TETANI; THIOMERSAL
ZOETIS AUSTRALIA PTY LTD
Cl perfringens toxoid (D)+Cl tetani - toxoid+Cl novyi type B + others
MISC. VACCINES OR ANTI SERA
CLOSTRIDIUM CHAUVOEI - FORMOL CULTURE VACCINE-MICROBIAL Active 0.0 P; CLOSTRIDIUM NOVYI TYPE B VACCINE-MICROBIAL Active 0.0 P; CLOSTRIDIUM PERFRINGENS TYPE D TOXOID VACCINE-TOXOID Active 0.0 P; CLOSTRIDIUM SEPTICUM - TOXOID VACCINE-TOXOID Active 0.0 P; TETANUS = CLOSTRIDIUM TETANI VACCINE-TOXOID Active 0.0 P; THIOMERSAL MERCURY Other 0.1 mg/ml
100mL; 250mL; 500mL; 50mL
VM - Veterinary Medicine
ZOETIS AUSTRALIA
CATTLE | SHEEP | SHEEP RAM (MALE) | BEEF | BOS INDICUS | BOS TAURUS | BOVINE | BUFFALO | BULL | BULLOCK | CALF | COW | DAIRY COW
IMMUNOTHERAPY
BLACK DISEASE | BLACKLEG | ENTEROTOXAEMIA (PULPY KIDNEY) | MALIGNANT OEDEMA | SWELLED HEAD | TETANUS | VACCINE | CLOSTRIDIUM PERFRINGENS TYPE D | EQUINE ROTAVIRUS | TETANUS VACCINATION
Poison schedule: 0; Withholding period: Meat: Zero (0) days MILK: Zero (0) days Zero (0) days; Host/pest details: CATTLE: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, VACCINE]; SHEEP: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, VACCINE]; SHEEP RAM (MALE): [SWELLED HEAD]; Poison schedule: 0; Withholding period: WHP: NIL; Host/pest details: CATTLE: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, VACCINE]; SHEEP: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, VACCINE]; SHEEP RAM (MALE): [SWELLED HEAD]; Poison schedule: 0; Withholding period: ; Host/pest details: CATTLE: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, VACCINE]; SHEEP: [BLACK DISEASE, BLACKLEG, ENTEROTOXAEMIA (PULPY KIDNEY), MALIGNANT OEDEMA, TETANUS, VACCINE]; SHEEP RAM (MALE): [SWELLED HEAD]; For the prevention of enterotoxaemia (pulpy kidney disease), tetanus, black disease, malignant oedema (blackleg like disease) and blackleg in cattle and sheep, including swelled head in rams.
Registered
2023-07-01
APPENDIX2 Australian Government Australian Pesticides and Veterinary Medicines Authority TEMPLATE FOR RELEVANT LABEL PARTICULARS (RLPs) (Veterinary Products) Select appropriate: [] New Product (include all applicable RLPs) OR 0 Variation (highlight instructions that are being varied). Approval no. of label being varied: 51279/1 [2,3.4]10509 Signal heading: Product name: Active constituent/s: Statement of claims: Net contents: Directions for Use Heading: Restraints: Contraindications: Precautions: Side effects: Dosage & administration: FOR ANIMAL TREATMENT ONLY Ultravac® 5 in 1 Vaccine Ultravac 5in1 is a multicomponent adjuvanted product containing Clostridium perfringens typeD<: 51U/mL Cl. tetani <: 2.51U/mL, Cl. novyi type B <:3.51U/mL, Cl. septicum <:2.51U/mL (as ultrafiltered toxoids) and Cl. chauvoei 0.3mL/mL (as formol culture). The adjuvant, which is an aluminium salt, increases the level and duration of the immunity conferred by the vaccine. The type of adjuvant and the purification procedures used ensure maximum protection of stock with minimum risk of local reactions at the site of injection. Thiomersal 0.1 mg/mL is added as a preservative. For the prevention of enterotoxaemia (pulpy kidney disease), tetanus, black disease, malignant oedema (blackleg-like disease) and blackleg in cattle and sheep including swelled head in rams 50mL, 100mL, 250 mL and 500 mL DIRECTIONS FOR USE READ ENCLOSED LEAFLET BEFORE USING THIS PRODUCT RLl Contents must be left in outer package until immediately before use. A,.,,.HV Shake well before use and keep thoroughly mixed during use. It is important that the vaccine is kept properly mixed before and during use. Before vaccine is injected, the proposed site of inoculation on the animal's skin may be cleaned by swabbing with cotton-wool soaked in an antiseptic solution, such as methylated spirits. N/A N/A N/A Localised swelling may develop at the site of injection and a firm nodular lump may persist for some weeks or even months. The route of inoculation is subcutaneous Uust u Lugege kogu dokumenti
PRODUCT NAME: ULTRAVAC ® 5 IN 1 VACCINE PAGE: 1 OF 5 THIS REVISION ISSUED: APRIL, 2010 MATERIAL SAFETY DATA SHEET Issued by: Pfizer Australia Pty Ltd Phone: (02)9850 3333 SECTION 1 - IDENTIFICATION OF CHEMICAL PRODUCT AND COMPANY Pfizer Australia Pty Ltd 38-42 Wharf Road West Ryde NSW 2114 Tel: (02) 9850 3333 Fax: (02) 9850 3399 ____________________________________ PFIZER AUSTRALIA PTY LTD A.B.N. 50 008 422 348 SUBSTANCE: Water solution/suspension of bacterial toxoids. TRADE NAME: ULTRAVAC ® 5 IN 1 VACCINE OTHER NAMES: _Cl. perfringens_ Type D, _Cl. tetani, Cl. septicum, Cl. novyi_ Type B, _Cl. chauvoei_ Vaccine PFIZER MSDS CODE: 0711 PRODUCT USE: For the prevention of clostridial diseases in sheep and cattle. CREATION DATE: DECEMBER, 2004 THIS VERSION ISSUED: APRIL, 2010 and is valid for 5 years from this date. SECTION 2 - HAZARDS IDENTIFICATION STATEMENT OF HAZARDOUS NATURE This product is classified as: Not classified as hazardous according to the criteria of SWA Australia. Not a Dangerous Good according to the Australian Dangerous Goods (ADG) Code. RISK PHRASES: Not Hazardous - No criteria found. SAFETY PHRASES: Not Hazardous - No criteria found. SUSDP CLASSIFICATION: None (Aust); S2 (NZ) ADG CLASSIFICATION: None allocated. Not a Dangerous Good. UN NUMBER: None allocated E E E M M M E E E R R R G G G E E E N N N C C C Y Y Y O O O V V V E E E R R R V V V I I I E E E W W W PHYSICAL DESCRIPTION & COLOUR : Aqueous suspension. ODOUR: No data. MAJOR HEALTH HAZARDS: no significant risk factors have been found for this product. P P P O O O T T T E E E N N N T T T I I I A A A L L L H H H E E E A A A L L L T T T H H H E E E F F F F F F E E E C C C T T T S S S INACTIVATED CULTURES AND TOXOIDS ARE NOT REGARDED AS PATHOGENIC IN HUMANS. INHALATION SHORT TERM EXPOSURE: Significant inhalation exposure is considered to be unlikely. The spray mist may be discomforting to the upper respiratory tract and lungs, and repeated exposure may cause sensitisation and/or allergic/asthma-like response. LONG TERM EXPOSURE: No data for h Lugege kogu dokumenti